<DOC>
	<DOCNO>NCT01235039</DOCNO>
	<brief_summary>The primary objective study test bioequivalence VIAject®7 VIAject®25 compare pharmacokinetic/Pharmacodynamic/tolerability characteristic VIAject®7 VIAject®25 insulin lispro .</brief_summary>
	<brief_title>A Study Evaluating Bioequivalence VIAject®7 Compared VIAject®25 Comparing Pharmacokinetic Pharmacodynamic Properties VIAject®7 Insulin Lispro Subjects With Type 1 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<criteria>Age : ≥19 ≤65 year Body Mass Index : ≥18 ≤28 kg/m2 Diagnosed Type 1 Diabetes Mellitus least 1 year Insulin antibody less equal 10 µU/mL screen Nonsmoker , define nicotine consumption least one year . Signed date informed consent obtain trialrelated activity . ( Trialrelated activity procedure would perform normal management subject ) Type 2 Diabetes Mellitus Cpeptide value &gt; 1.0 ng/mL HbA1c value &gt; 10.0 % History hypersensitivity component study medication History severe multiple allergy Treatment investigational drug last 3 month study entry Any systemic treatment drug know interfere glucose metabolism systemic corticoid , nonselective betablockers , monoamine oxidase ( MAO ) inhibitor within 3 month prior randomization . Changes ( type drug dose ) concomitant medication insulin insulin analogue last 3 week prior randomization . Use nonprescription drug , except routine vitamin , within 3 week prior first dose test drug . Occasional use paracetamol/acetaminophen permit . Progressive disease likely prove fatal ( e.g . malignancy ) Current drug alcohol abuse , history drug alcohol abuse opinion Investigator impair subject safety protocol compliance Significant cardiovascular , respiratory , gastrointestinal , hepatic , renal , neurological , psychiatric and/or hematological disease evaluate Investigator Clinically significant abnormal hematology biochemistry screen test , judge Investigator . In particular , subject elevate liver enzymes ( AST ALT &gt; 2 time upper limit normal ) impair renal function ( serum creatinine value upper limit normal ) allow enter trial . Any serious systemic infectious disease four week prior first dose study drug , judge Investigator . History illness , opinion Investigator , might confound result trial pose risk administer trial drug subject . In particular , subject significant cardiovascular disease , anemia ( hemoglobin low limit normal ) hemoglobinopathy allow enter trial . Blood donation within last 30 day A woman lactate Pregnant woman woman intend become pregnant study A sexually active woman use adequate contraceptive method ( adequate contraceptive measure include : implant , injectables , combine oral contraceptive , hormonal intrauterine device [ IUD ] , sexual abstinence vasectomize partner ) Positive serology HIV , Hepatitis B Hepatitis C Abnormal ECG , safety lab physical examination result deem clinically significant Investigator Lack compliance reason , opinion Investigator , prevent participation subject study .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>